Drug Profile

PS 002

Alternative Names: PS-002

Latest Information Update: 22 Dec 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Purespring Therapeutics
Class Gene therapies; Urologics
Mechanism of Action Complement factor I replacements; Gene transference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - IgA nephropathy
New Molecular Entity No

Highest Development Phases

Phase I/II IgA nephropathy

Most Recent Events

28 Nov 2025 Phase-I/II clinical trials in IgA nephropathy (Treatment-experienced) in United Kingdom (Parenteral) (NCT07182227)
27 Oct 2025 Chromatin Bioscience and Purespring Therapeutics enters into a collaboration for chromatinLENS platform
23 Sep 2025 Purespring Therapeutics plans a phase I/II trial for PS 002 in IgA nephropathy in USA and United Kingdom in October 2025 (NCT07182227) (EudraCT2025-523201-14-00)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com